Adicet Bio, Inc.
Adicet Bio, Inc. (ACET) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
acet · stock forecast · 12 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Buy
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$18.00
Consensus
$18.00
+149.3% upside
Low
$18.00
Median: $18 · Last Close: $7.22
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $7.04 | ↓ 2.51% |
1-day model range: $6.89–$7.19. Peak: $7.19 (-2.51%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · ACET · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-13 | Guggenheim | Maintains | Buy→Buy |
| 2026-01-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-01-06 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-11-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-08 | Guggenheim | Maintains | Buy→Buy |
| 2025-09-19 | Guggenheim | Maintains | Buy→Buy |
| 2025-03-21 | Guggenheim | Maintains | Buy→Buy |
| 2025-03-07 | Citizens Capital Markets | Maintains | Market Perform→Market Perform |
| 2025-03-07 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on Adicet Bio, Inc. (ACET) stock. Of the recent 53 rating actions, 0 were upgrades and 3 were downgrades. 12 analysts currently cover ACET.
Analyst Recommendation Trends
ACET analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$3M
↓ 96.6% YoY
Revenue Next Year
$34M
↑ 1097.9% YoY
EPS This Year
$-8.34
EPS Next Year
$-3.67
↓ 56.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast ACET EPS of $-8.34 for the current fiscal year, based on estimates from 4 analysts. The ACET revenue forecast is $3M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ACET stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ACET price target is $18.00 (+149.3% upside), with an analyst consensus of Buy.
The ACET short-term stock prediction for tomorrow is $7.04 (-2.51%). The ACET stock prediction for 2030 projects a range of $2–$2.
Adicet Bio, Inc. trades on NASDAQ under the ticker ACET. The ACET stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.
Frequently asked questions
ACET forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month ACET price target is $18.00, with a high forecast of $18.00 and a low of $18.00. The median price target is shown in the chart above when available. This implies +149.3% potential upside from the current price of $7.22.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.